Literature DB >> 25511321

Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.

Mixue Xie1, Kefei Wu, Yan Liu, Qi Jiang, Yanhui Xie.   

Abstract

F-18 fluorodeoxyglucose (FDG) positron emission tomography/computerized tomography (PET/CT) is considered to be the most beneficial imaging method for staging patients with lymphoma. Whether maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) acquired from F-18 FDG PET/CT are predictors of prognosis of diffuse large B cell lymphoma (DLBCL) is controversial, with some studies concluding that it is and others concluding the opposite. Therefore, a systematic review was performed to explore the relationship of F-18 FDG PET/CT quantization parameters with the prognosis of DLBCL. Seven trials with a total of 703 DLBCL patients were included for analysis. Hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS), and odds ratios (ORs) for 3-year PFS and OS were pooled using the STATA package. Combined results suggested a strong link between the high SUVmax, MTV and TLG values and the poor 3-year PFS with ORs of 2.59, 3.69 and 2.29, respectively. Similarly, high MTV and TLG values unfavorably influenced the 3-year OS with ORs of 5.40 and 2.19, respectively. The pooled results also showed that high SUVmax and MTV were negative predictors of PFS with HRs of 1.61 (p = 0.038) and 2.18 (p = 0.000), respectively. The TLG value was not predictive of PFS. And for OS, only high MTV was a strong predictor of poor prognosis in DLBCL with HR 2.99 (p = 0.000). Our results suggested that SUVmax and MTV may be significant prognostic markers for PFS and MTV may be the only predictor for OS in DLBCL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25511321     DOI: 10.1007/s12032-014-0446-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  25 in total

1.  High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma.

Authors:  Dai Chihara; Yasuhiro Oki; Hiroshi Onoda; Hirofumi Taji; Kazuhito Yamamoto; Tsuneo Tamaki; Yasuo Morishima
Journal:  Int J Hematol       Date:  2011-04-06       Impact factor: 2.490

2.  Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters.

Authors:  Seung Hwan Moon; Joon Young Choi; Hwan Joo Lee; Young-Ik Son; Chung-Hwan Baek; Yong Chan Ahn; Keunchil Park; Kyung-Han Lee; Byung-Tae Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

3.  Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Elisabeth Ralfkiaer; Lena Specht
Journal:  Hematol Oncol       Date:  2006-09       Impact factor: 5.271

Review 4.  Standards for PET image acquisition and quantitative data analysis.

Authors:  Ronald Boellaard
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.

Authors:  N G Mikhaeel; A R Timothy; M J O'Doherty; S Hain; M N Maisey
Journal:  Leuk Lymphoma       Date:  2000-11

7.  Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.

Authors:  A Bari; L Marcheselli; S Sacchi; R Marcheselli; S Pozzi; P Ferri; E Balleari; P Musto; S Neri; M A Aloe Spiriti; M C Cox
Journal:  Ann Oncol       Date:  2009-11-17       Impact factor: 32.976

Review 8.  Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease?

Authors:  M A Shipp
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

9.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.

Authors:  Moo-Kon Song; Joo-Seop Chung; Ho-Jin Shin; Sang-Min Lee; Su-Ee Lee; Ho-Sup Lee; Gyeong-Won Lee; Seong-Jang Kim; Seok-Mo Lee; Dong-Seop Chung
Journal:  Ann Hematol       Date:  2011-11-11       Impact factor: 3.673

10.  Clinical significance of standardized uptake value and maximum tumor diameter in patients with primary extranodal diffuse large B cell lymphoma.

Authors:  Min-Young Oh; Sang-Bo Oh; Hyeog-Gyu Seoung; Ji-Hye Kim; Sang-Mi Kim; Tae-Kyun Kim; Moo-Kon Song; Ho-Jin Shin; Joo-Seop Chung
Journal:  Korean J Hematol       Date:  2012-09-25
View more
  20 in total

1.  Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.

Authors:  Pierre Decazes; Stéphanie Becker; Mathieu Nessim Toledano; Pierre Vera; Paul Desbordes; Fabrice Jardin; Hervé Tilly; Isabelle Gardin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-28       Impact factor: 9.236

2.  Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Authors:  Qaid Ahmed Shagera; Gi Jeong Cheon; Youngil Koh; Min Young Yoo; Keon Wook Kang; Dong Soo Lee; E Edmund Kim; Sung-Soo Yoon; June-Key Chung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

3.  PET-derived tumor metrics predict DLBCL response and progression-free survival.

Authors:  Prioty Islam; Jordan Goldstein; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-02-04

4.  Association between tumor necrosis factor-α gene polymorphisms and diffuse large B-cell lymphoma in Chinese Han population: evidence from two center case-control study and a meta-analysis.

Authors:  Cui Yang; Wanling Wang; Youmei Zi; Xiaolin Han; Xiaoxue Qin; Jingdong Li; Honggang Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

5.  High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.

Authors:  Erin A Dean; Rahul S Mhaskar; Hong Lu; Mina S Mousa; Gabriel S Krivenko; Aleksandr Lazaryan; Christina A Bachmeier; Julio C Chavez; Taiga Nishihori; Marco L Davila; Farhad Khimani; Hien D Liu; Javier Pinilla-Ibarz; Bijal D Shah; Michael D Jain; Yoganand Balagurunathan; Frederick L Locke
Journal:  Blood Adv       Date:  2020-07-28

6.  Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma.

Authors:  Jorge E Jimenez; Dong Dai; Guofan Xu; Ruiyang Zhao; Tengfei Li; Tinsu Pan; Linghua Wang; Yingyan Lin; Zhangyang Wang; David Jaffray; John D Hazle; Homer A Macapinlac; Jia Wu; Yang Lu
Journal:  Clin Nucl Med       Date:  2022-03-01       Impact factor: 7.794

7.  Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.

Authors:  Lale Kostakoglu; Federico Mattiello; Maurizio Martelli; Laurie H Sehn; David Belada; Chiara Ghiggi; Neil Chua; Eva González-Barca; Xiaonan Hong; Antonio Pinto; Yuankai Shi; Yoichi Tatsumi; Christopher Bolen; Andrea Knapp; Gila Sellam; Tina Nielsen; Deniz Sahin; Umberto Vitolo; Marek Trněný
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

8.  Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Chiara Pagani; Alessandro Re; Alessandra Tucci; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-02       Impact factor: 9.236

9.  Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas.

Authors:  Marie Tosolini; Christelle Algans; Frédéric Pont; Bernard Ycart; Jean-Jacques Fournié
Journal:  Oncoimmunology       Date:  2016-05-19       Impact factor: 8.110

10.  Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma.

Authors:  Mathieu Nessim Toledano; P Desbordes; A Banjar; I Gardin; P Vera; P Ruminy; F Jardin; H Tilly; S Becker
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.